Harold Mastalerz - Concepedia

Author

Harold Mastalerz

Bristol-Myers Squibb (United States)

Also Known As

H Mastalerz, H. MASTALERZ, H. Mastalerz, HAROLD MASTALERZ, Harold A. Mastalerz, Harold Mastalerz, Mastalerz, Harold.

Publications

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (Canada)

About

Harold Mastalerz is an author at Bristol-Myers Squibb (United States) specializing in natural sciences, pharmacology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	13	13	460
2	Medicine	12	14	464
3	Biochemistry	9	9	344
4	Engineering	5	5	122
5	Public Health	1	1	11

Harold Mastalerz

Publications

861

Citations

H-Index

Page 1

	Year	Citations
Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains Dalton King, Gene M. Dubowchik, Harold Mastalerz, Journal of Medicinal Chemistry Peptide EngineeringImmunologyMolecular BiologyPeptide ScienceChemical Biology	2002	134
Discovery of a 2,4-Disubstituted Pyrrolo[1,2-<i>f</i>][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development Mark D. Wittman, Joan M. Carboni, Yang Zheng, Journal of Medicinal Chemistry	2009	94
Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling Tai W. Wong, Francis Y. Lee, Chiang Yu, Clinical Cancer Research	2006	78
An examination of O-2-isocephems as orally absorbable antibiotics Harold Mastalerz, Marcel Ménard, Vivianne Vinet, Journal of Medicinal Chemistry Analogous CephemsMedicinal ChemistryPharmaceutical ScienceAntibioticsBiochemistry	1988	48
The discovery of BMS-275183: an orally efficacious novel taxane Harold Mastalerz, Donald J. Cook, Craig R. Fairchild, Bioorganic & Medicinal Chemistry BiologyNatural SciencesMolecular BiologySecondary MetaboliteEfficacious Novel Taxane	2003	47
New dual inhibitors of EGFR and HER2 protein tyrosine kinases Brian E. Fink, Gregory D. Vite, Harold Mastalerz, Bioorganic & Medicinal Chemistry Letters Signal TransductionSignaling PathwayMedicineReceptor Tyrosine KinaseCancer Growth	2005	43
Palladium-catalyzed conversion of esters of 4-(trimethylsilyl)-2-buten-1-ol to trimethylsilyl esters: a new carboxyl protecting group Harold Mastalerz The Journal of Organic Chemistry Palladium-catalyzed ConversionNew CarboxylEngineeringCross-coupling ReactionDonut Icon	1984	37
New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Harold Mastalerz, Ming Chang, Ping Chen, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesNew C-5	2007	37
Discovery and Preclinical Evaluation of [4-[[1-(3-fluorophenyl)methyl]-1<i>H</i>-indazol-5-ylamino]-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yl]carbamic Acid, (3<i>S</i>)-3-Morpholinylmethyl Ester (BMS-599626), a Selective and Orally Efficacious Inhibitor of Human Epidermal Growth Factor Receptor 1 and 2 Kinases Ashvinikumar V. Gavai, Brian E. Fink, David J. Fairfax, Journal of Medicinal Chemistry Orally Efficacious InhibitorKinase InhibitorsPharmacotherapyDermatologyPharmaceutical Chemistry	2009	29
5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Harold Mastalerz, Ming Chang, Ping Chen, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesReceptor Tyrosine Kinase	2007	29

Page 1